155 related articles for article (PubMed ID: 38364453)
21. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.
Friedman KM; Prieto PA; Devillier LE; Gross CA; Yang JC; Wunderlich JR; Rosenberg SA; Dudley ME
J Immunother; 2012 Jun; 35(5):400-8. PubMed ID: 22576345
[TBL] [Abstract][Full Text] [Related]
22. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
Schiltz PM; Beutel LD; Nayak SK; Dillman RO
J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
[TBL] [Abstract][Full Text] [Related]
23. CD4
Lu J; Huang C; He R; Xie R; Li Y; Guo X; Zhang Q; Xu Q
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9007-9016. PubMed ID: 37165118
[TBL] [Abstract][Full Text] [Related]
24. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
25. Tumor infiltrating lymphocytes and continuous infusion interleukin-2 after metastasectomy in 61 patients with melanoma, colorectal and renal carcinoma.
Fabbri M; Ridolfi R; Maltoni R; Ridolfi L; Riccobon A; Flamini E; De Paola F; Verdecchia GM; Amadori D
Tumori; 2000; 86(1):46-52. PubMed ID: 10778766
[TBL] [Abstract][Full Text] [Related]
26. Peripheral blood and tumor infiltrating lymphocytes in non-small cell lung cancer: analysis at the population and clonal level.
Viale M; Ferrini S; Serrano S; Serrano D; Ardizzoni A; Nicolin A
Tumori; 1990 Oct; 76(5):488-94. PubMed ID: 2175060
[TBL] [Abstract][Full Text] [Related]
27. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients.
Ellebaek E; Iversen TZ; Junker N; Donia M; Engell-Noerregaard L; Met Ö; Hölmich LR; Andersen RS; Hadrup SR; Andersen MH; thor Straten P; Svane IM
J Transl Med; 2012 Aug; 10():169. PubMed ID: 22909342
[TBL] [Abstract][Full Text] [Related]
28. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.
Schwartzentruber DJ; Hom SS; Dadmarz R; White DE; Yannelli JR; Steinberg SM; Rosenberg SA; Topalian SL
J Clin Oncol; 1994 Jul; 12(7):1475-83. PubMed ID: 8021739
[TBL] [Abstract][Full Text] [Related]
29. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
30. TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.
Kongkaew T; Thaiwong R; Tudsamran S; Sae-Jung T; Sengprasert P; Vasuratna A; Suppipat K; Reantragoon R
J Immunol Methods; 2022 Apr; 503():113229. PubMed ID: 35101548
[TBL] [Abstract][Full Text] [Related]
31. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response.
Pockaj BA; Sherry RM; Wei JP; Yannelli JR; Carter CS; Leitman SF; Carasquillo JA; Steinberg SM; Rosenberg SA; Yang JC
Cancer; 1994 Mar; 73(6):1731-7. PubMed ID: 8156501
[TBL] [Abstract][Full Text] [Related]
32. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
Mayor P; Starbuck K; Zsiros E
Gynecol Oncol; 2018 Aug; 150(2):361-369. PubMed ID: 29803316
[TBL] [Abstract][Full Text] [Related]
33. Growth and autologous tumor lysis by tumor-infiltrating lymphocytes from metastatic melanoma expanded in interleukin-2 or interleukin-2 plus interleukin-4.
Lindgren CG; Thompson JA; Higuchi CM; Fefer A
J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):322-8. PubMed ID: 8280715
[TBL] [Abstract][Full Text] [Related]
34. In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice.
Wong RA; Alexander RB; Puri RK; Rosenberg SA
J Immunother (1991); 1991 Apr; 10(2):120-30. PubMed ID: 2043592
[TBL] [Abstract][Full Text] [Related]
35. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.
Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY
PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825
[TBL] [Abstract][Full Text] [Related]
36. Recruitment of host CD8+ T cells by tumor-infiltrating lymphocytes and recombinant interleukin-2 during adoptive immunotherapy of cancer.
Burger UL; Chang MP; Goedegebuure PS; Eberlein TJ; Adams-Hodgins S
Surgery; 1995 Mar; 117(3):325-33. PubMed ID: 7878540
[TBL] [Abstract][Full Text] [Related]
37. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.
Aydin AM; Hall M; Bunch BL; Branthoover H; Sannasardo Z; Mackay A; Beatty M; Sarnaik AA; Mullinax JE; Spiess PE; Pilon-Thomas S
Int Immunopharmacol; 2021 May; 94():107481. PubMed ID: 33636562
[TBL] [Abstract][Full Text] [Related]
38. A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
Deniger DC; Kwong ML; Pasetto A; Dudley ME; Wunderlich JR; Langhan MM; Lee CR; Rosenberg SA
Clin Cancer Res; 2017 Jan; 23(2):351-362. PubMed ID: 28093487
[TBL] [Abstract][Full Text] [Related]
39. High intratumoral CD8
Yang Y; Attwood K; Bshara W; Mohler JL; Guru K; Xu B; Kalinski P; Chatta G
Prostate; 2021 Jan; 81(1):20-28. PubMed ID: 33085799
[TBL] [Abstract][Full Text] [Related]
40. Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes.
Chakraborty NG; Sporn JR; Pasquale DR; Ergin MT; Mukherji B
Clin Immunol Immunopathol; 1991 Jun; 59(3):407-16. PubMed ID: 2029793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
